Volume 26, Issue 1 (Iranian South Medical Journal 2023)
Iran South Med J 2023, 26(1): 51-62 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shahbazi F, Heydarpour F, Kamari A, Azizi M, Bahremand M, Shojaei L. Comparison of the Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients with or Susceptible to Thromboembolic Events. Iran South Med J 2023; 26 (1) :51-62
URL: http://ismj.bpums.ac.ir/article-1-1794-en.html
URL: http://ismj.bpums.ac.ir/article-1-1794-en.html
Foroud Shahbazi1 
, Fatemeh Heydarpour2 , Amir Kamari3 , Mohammad Azizi3 , Mostafa Bahremand4 , Lida Shojaei * 5
, Fatemeh Heydarpour2 , Amir Kamari3 , Mohammad Azizi3 , Mostafa Bahremand4 , Lida Shojaei * 5
1- Department of Clinical Pharmacy, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
2- Medical Biology Research Center, Health Technology Institute, Kermanshah University of medical Sciences, Kermanshah, Iran
3- Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran
4- Clinical Research Development Center, Imam Ali and Taleghani Hospital, Kermanshah University of Medical Sci-ences, Kermanshah, Iran
5- Department of Clinical Pharmacy, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
Clinical Research Development Center, Imam Ali and Taleghani Hospital, Kermanshah University of Medical Sci-ences, Kermanshah, Iran , shojaeilida99@gmail.com
2- Medical Biology Research Center, Health Technology Institute, Kermanshah University of medical Sciences, Kermanshah, Iran
3- Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran
4- Clinical Research Development Center, Imam Ali and Taleghani Hospital, Kermanshah University of Medical Sci-ences, Kermanshah, Iran
5- Department of Clinical Pharmacy, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
Clinical Research Development Center, Imam Ali and Taleghani Hospital, Kermanshah University of Medical Sci-ences, Kermanshah, Iran , shojaeilida99@gmail.com
Abstract: (612 Views)
Background: The similar efficacy of rivaroxaban and warfarin in thromboembolic events was recognized in clinical trials. But there are a few studies about the comparison of these medications in real world. This study was designed with the aim of comparing the efficacy and safety of the rivaroxaban and warfarin.
Materials and Methods: All patients who received rivaroxaban or warfarin during April 2019 and October 2020 were recruited in the study. The major bleeding and thromboembolic events were considered as primary outcomes. Secondary outcomes were all cause mortality and minor bleeding. All of patients were followed for six months after recruitment and the end of study.
Results: Of 242 patients recruited during the 18 months, 116 patients received rivaroxaban and 126 received warfarin. There were no significant differences between warfarin and rivaroxaban regarding major bleeding (p=0.24) and thromboembolic events (p=0.38). The minor bleeding was significantly higher in warfarin group. (29.36% versus 12.93%, p=0.002). The all-cause mortality rate was similar between two groups (p=0.67). More than 12% of patients were discontinued rivaroxaban, due to high cost. In warfarin group, 14.28% patients did not have compliance due to laboratory fluctuations and inappropriate access to medication.
Conclusion: In the present study, warfarin and rivaroxaban had similar efficacy and safety. In addition, suitable compliance was observed in both groups.
Materials and Methods: All patients who received rivaroxaban or warfarin during April 2019 and October 2020 were recruited in the study. The major bleeding and thromboembolic events were considered as primary outcomes. Secondary outcomes were all cause mortality and minor bleeding. All of patients were followed for six months after recruitment and the end of study.
Results: Of 242 patients recruited during the 18 months, 116 patients received rivaroxaban and 126 received warfarin. There were no significant differences between warfarin and rivaroxaban regarding major bleeding (p=0.24) and thromboembolic events (p=0.38). The minor bleeding was significantly higher in warfarin group. (29.36% versus 12.93%, p=0.002). The all-cause mortality rate was similar between two groups (p=0.67). More than 12% of patients were discontinued rivaroxaban, due to high cost. In warfarin group, 14.28% patients did not have compliance due to laboratory fluctuations and inappropriate access to medication.
Conclusion: In the present study, warfarin and rivaroxaban had similar efficacy and safety. In addition, suitable compliance was observed in both groups.
Type of Study: Original |
Subject:
Cardiovascular System
Received: 2023/04/17 | Accepted: 2023/11/4 | Published: 2023/11/8
Received: 2023/04/17 | Accepted: 2023/11/4 | Published: 2023/11/8
References
1. Rivaroxaban: Drug information. Lexicomp. (Accessed january 2023, at https://medilib.ir/uptodate/show/9498) [Article]
2. Tadros R, Shakib S. Warfarin--indications, risks and drug interactions. Aust Fam Physician 2010; 39(7): 476-9. [PubMed]
3. Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring. Proc (Bayl Univ Med Cent) 2001; 14(3): 305-6. [DOI]
4. Barón-Esquivias G, Marín F, Sanmartín Fernandez M. Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice. Expert Rev Cardiovasc Ther 2017; 15(5): 403-13. [DOI]
5. Chen ST, Hellkamp AS, Becker RC, et al. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care Clin Outcomes 2019; 5(2): 145-52. [DOI]
6. Tabatabaie SA, Asharin MR, Assadi M, et al. Comparsion of influence of enoxaparin with unfractioned heparin on acute myocardial infarction with ST-segment elevation. Iran South Med J 2009; 12(3): 198-205. (Persian) [Article]
7. Liu PH, Liu ZH, Niu MH, et al. A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk. Front Cardiovasc Med 2022; 9: 803233. [DOI]
8. Perales IJ, San Agustin K, DeAngelo J, et al. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight. Ann Pharmacother 2020; 54(4): 344-50. [DOI]
9. Weir MR, Ashton V, Moore KT, et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. Am Heart J 2020; 223: 3-11. [DOI]
10. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91. [DOI]
11. Brown JD, Goodin AJ, Lip GYH, et al. Risk stratification for bleeding complications in patients with venous thromboembolism: application of the HAS‐BLED bleeding score during the first 6 months of anticoagulant treatment. J Am Heart Assoc 2018; 7(6): e007901. [DOI]
12. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57(2): 173-80. [DOI]
13. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost 2005; 3(4): 692-4. [DOI]
14. Metzgier-Gumiela A, Skonieczny G, Konieczyńska M, et al. Minor bleeding affects the level of knowledge in patients with atrial fibrillation on oral anticoagulant therapy. Int J Clin Pract 2020; 74(6): e13483. [DOI]
15. Alberts MJ, He J, Kharat A, et al. Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy. Am J Cardiovasc Drugs 2022; 22(4): 425-36. [DOI]
16. Coleman CI, Turpie AGG, Bunz TJ, et al. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2- VASc score of 1. Eur Heart J Cardiovasc Pharmacother 2019; 5(2): 64-9. [DOI]
17. Vinogradova Y, Coupland C, Hill T, et al. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ 2018; 362: k2505. [DOI]
18. Hong KS, Kwon SU, Lee SH, et al. Rivaroxaban vs Warfarin Sodium in the UltraEarly Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol 2017; 74(10): 1206-15. [DOI]
19. Gorst-Rasmussen A, Lip GY, Bjerregaard Larsen T. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf 2016; 25(11): 1236-44. [DOI]
20. Norby FL, Bengtson LGS, Lutsey PL, et al. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord 2017; 17(1): 238. [DOI]
21. Coleman CI, Thompson S, Ashton V, et al. Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation. J Natl Med Assoc 2020; 112(4): 395-401. [DOI]
22. Russo-Alvarez G, Martinez KA, Valente M, et al. Thromboembolic and Major Bleeding Events With Rivaroxaban Versus Warfarin Use in a Real-World Setting. Ann Pharmacother 2018; 52(1): 19-25. [DOI]
23. Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, et al. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis 2013; 2013: 640723. [DOI]
24. Bai Y, Deng H, Shantsila A, et al. Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis. Stroke 2017; 48(4): 970-6. [DOI]
25. Peterson ED, Ashton V, Chen YW, et al. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. Am Heart J 2019; 212: 113-9. [DOI]
26. Yao X, Abraham NS, Alexander GC, et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc 2016; 5(2): e003074. [DOI]
27. Gordan H, Beyranvand MR, Sheibani M, et al. Cost Effectiveness of Rivaroxaban versus Warfarin to Prevent Stroke in Iranian AF Patients. Sch Med Stud J 2020; 2(3): 18-24. [DOI]
28. Jaberi N, Kavosi Z, Hooshmandi E, et al. The study of cost-effectiveness of rivaroxaban versus warfarin in patients with atrial fibrillation who developed ischemic stroke. Stroke Res Treat 2021; 2021: 5534873. [DOI]
29. Khorvash F, Farajpour-Khanaposhtani MJ, Hemasian H, et al. Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study. Curr J Neurol 2021; 20(3): 125-30. [DOI]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
